suMMARY The effects of the new calcium channel blocking agent diltiazem were evaluated in 11 patients with stable angina pectoris and confirmed obstructive coronary artery disease at rest and during rapid atrial pacing. Symptomatic, metabolic, coronary, and systemic haemodynamic indices were monitored at rest and during pacing induced ischaemia. At rest, after the administration of intravenous diltiazem, potent vasodilator effects were observed with a significant fall in mean blood pressure and an increase in cardiac index. Importantly, however, the systemic vasodilator effect of diltiazem was associated with no significant increase in heart rate. During pacing there was similar decrease in mean blood pressure after diltiazem, and mean pacing time to angina increased significantly. Three patients did not develop angina on repeat pacing. Coupled with an improved pacing time to angina there was a significant improvement in myocardial lactate extraction during pacing, changing from lactate production to lactate extraction after diltiazem.
suMMARY The effects of the new calcium channel blocking agent diltiazem were evaluated in 11 patients with stable angina pectoris and confirmed obstructive coronary artery disease at rest and during rapid atrial pacing. Symptomatic, metabolic, coronary, and systemic haemodynamic indices were monitored at rest and during pacing induced ischaemia. At rest, after the administration of intravenous diltiazem, potent vasodilator effects were observed with a significant fall in mean blood pressure and an increase in cardiac index. Importantly, however, the systemic vasodilator effect of diltiazem was associated with no significant increase in heart rate. During pacing there was similar decrease in mean blood pressure after diltiazem, and mean pacing time to angina increased significantly. Three Accepted for publication 13 March 1984 Diltiazem, a benzothiazepine derivative, is a new addition to the calcium channel blocking agents.5 Studies in dogs with artificially induced coronary arterial stenoses subjected to rapid cardiac pacing have indicated that diltiazem exerts a protective effect on the ischaemic myocardium by promoting a rapid recovery from ischaemia.6 Further animal studies have shown that it has a less negatively inotropic effect than either verapamil or nifedipine.8 Although in humans diltiazem improves exercise tolerance, its mechanism of action has not been clearly defined.9 10 We studied the effect of diltiazem on After the administration of diltiazem angina did not occur in three patients on repeat pacing. In the remaining patients, with the exception of one whose pacing time to angina remained virtually unchanged, the onset of angina was delayed. Consequently mean pacing time to angina after diltiazem was significantLy increased from 165 (49) to 455 (79) s (p<0O005) (Figure) .
The haemodynamic findings at rest in this study indi-* cate the potent vasodilator effect of diltiazem. A study Ls in dogs using intracoronary diltiazem showed it to Is have a negative inotropic effect, although this was less a than that produced by equimolar doses of nifedipine or verapamil.8 In this study cardiac output at rest * increased significantly after administration of the e drug, and there were no significant changes in pulmoe nary artery diastolic pressure suggesting the absence n of negative inotropy. Any negative inotropic effect might, however, have been offset by the positive inotropic effect of increased sympathetic discharge in response to systemic vasodilatation.
In this study systemic vasodilatation occurred without any significant change in resting heart rate. This is in contrast to an increase in resting heart rate seen after acutely administered nifedipine.'3 The absence of heart rate response to systemic vasodilatation after diltiazem has been reported in an exercise study of long term oral administration.9 In addition, electrophysiological studies have shown that diltiazem depresses sinoatrial node automaticity, and this may in part account for its effect on heart rate.14 This absence of an increase in heart rate and thus in myocardial oxygen demand may have important advantages in the management of angina pectoris.
In ischaemic heart disease angina may be induced by rapid atrial pacing and is associated with a change from aerobic to anaerobic metabolism. demand. In addition, by inhibiting the rise in myocardial calcium induced by ischaemia they may prevent or delay the consequences of ischaemia.2 In this study diltiazem did not produce any significant change in resting coronary sinus blood flow but resulted in a small but significant decrease during pacing. A similar effect has been reported with verapamil, which, although reducing coronary sinus flow at rest and during pacing, prolonged pacing time to angina and improved myocardial metabolism. '6 This would suggest that the antianginal effect is not due to increased coronary blood flow. In animal studies, however, under conditions simulating unstable angina pectoris, diltiazem increased collateral blood flow to collateral dependent myocardium. '7 We cannot exclude the possibility in this study that diltiazem caused a redistribution of the available blood supply by increasing collateral flow.
During pacing diltiazem reduced left ventricular afterload and rate pressure product. This might be expected to reduce myocardial oxygen consumption, as rate pressure product during pacing induced tachycardia is a good indicator of the level of myocardial oxygen demand. ' 8 Surprisingly, in this study we failed to show a significant reduction in myocardial oxygen consumption during pacing, although a trend towards reduction was seen. This suggests that diltiazem may have had a direct metabolic effect on the myocardium. The calcium antagonist nifedipine has been shown to have an antianginal effect unrelated to its effect on systemic and coronary haemodynamics indices,'9 perhaps through inhibition of calcium ion flux at a cellular level. In a similar way, diltiazem may have exerted a direct effect on the myocardium so delaying the onset or reducing the consequences of ischaemia. Our study design, however, did not permit evaluation of a possible beneficial effect at cellular level.
In conclusion, this study showed the potent vasodilator effect of diltiazem, which occurred without a significant change in resting heart rate. The beneficial effect in angina pectoris is indicated by an increased pacing time to angina and an improvement in myocardial metabolism. The results suggest that diltiazem acts by a combination of effects, such as afterload reduction and a direct effect in the myocardium. Diltiazem may have certain advantages over other presently available calcium channel blocking agents. It can be given both orally and intravenously, and a multicentre study to assess drug safety showed a low incidence of side effects.'0 Comparisons between diltiazem and other calcium channel blocking agents would be of interest. The results of this study indicate Kenny, Daly, Bergman, Kerkez, J7ewitt that diltiazem may well prove to be a very useful addition to the present treatment of angina pectoris.
